Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action

HER2 acts an oncogenic driver in numerous cancers. Here, the authors design an anti-HER2 biparatopic and tetravalent IgG fusion with inhibitory effects in a xenograft model.

Guardado en:

Detalles Bibliográficos
Autores principales:	Florian Kast, Martin Schwill, Jakob C. Stüber, Svende Pfundstein, Gabriela Nagy-Davidescu, Josep M. Monné Rodríguez, Frauke Seehusen, Christian P. Richter, Annemarie Honegger, Karen Patricia Hartmann, Thomas G. Weber, Felix Kroener, Patrick Ernst, Jacob Piehler, Andreas Plückthun
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/bbc4cba63fcc425a86335df0941f73d7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bbc4cba63fcc425a86335df0941f73d7
record_format	dspace
spelling	oai:doaj.org-article:bbc4cba63fcc425a86335df0941f73d72021-12-02T16:04:29ZEngineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action10.1038/s41467-021-23948-62041-1723https://doaj.org/article/bbc4cba63fcc425a86335df0941f73d72021-06-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-23948-6https://doaj.org/toc/2041-1723HER2 acts an oncogenic driver in numerous cancers. Here, the authors design an anti-HER2 biparatopic and tetravalent IgG fusion with inhibitory effects in a xenograft model.Florian KastMartin SchwillJakob C. StüberSvende PfundsteinGabriela Nagy-DavidescuJosep M. Monné RodríguezFrauke SeehusenChristian P. RichterAnnemarie HoneggerKaren Patricia HartmannThomas G. WeberFelix KroenerPatrick ErnstJacob PiehlerAndreas PlückthunNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-18 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Florian Kast Martin Schwill Jakob C. Stüber Svende Pfundstein Gabriela Nagy-Davidescu Josep M. Monné Rodríguez Frauke Seehusen Christian P. Richter Annemarie Honegger Karen Patricia Hartmann Thomas G. Weber Felix Kroener Patrick Ernst Jacob Piehler Andreas Plückthun Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
description	HER2 acts an oncogenic driver in numerous cancers. Here, the authors design an anti-HER2 biparatopic and tetravalent IgG fusion with inhibitory effects in a xenograft model.
format	article
author	Florian Kast Martin Schwill Jakob C. Stüber Svende Pfundstein Gabriela Nagy-Davidescu Josep M. Monné Rodríguez Frauke Seehusen Christian P. Richter Annemarie Honegger Karen Patricia Hartmann Thomas G. Weber Felix Kroener Patrick Ernst Jacob Piehler Andreas Plückthun
author_facet	Florian Kast Martin Schwill Jakob C. Stüber Svende Pfundstein Gabriela Nagy-Davidescu Josep M. Monné Rodríguez Frauke Seehusen Christian P. Richter Annemarie Honegger Karen Patricia Hartmann Thomas G. Weber Felix Kroener Patrick Ernst Jacob Piehler Andreas Plückthun
author_sort	Florian Kast
title	Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
title_short	Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
title_full	Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
title_fullStr	Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
title_full_unstemmed	Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
title_sort	engineering an anti-her2 biparatopic antibody with a multimodal mechanism of action
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/bbc4cba63fcc425a86335df0941f73d7
work_keys_str_mv	AT floriankast engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT martinschwill engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT jakobcstuber engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT svendepfundstein engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT gabrielanagydavidescu engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT josepmmonnerodriguez engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT fraukeseehusen engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT christianprichter engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT annemariehonegger engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT karenpatriciahartmann engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT thomasgweber engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT felixkroener engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT patrickernst engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT jacobpiehler engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction AT andreaspluckthun engineeringanantiher2biparatopicantibodywithamultimodalmechanismofaction
_version_	1718385229795688448

Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action

Ejemplares similares